Increased risk of adverse drug events secondary to bevacizumab treatment in patients with advanced or metastatic breast cancer: a meta-analysis of randomized controlled trials
Sooyoung Shin,1,2 Yoojin Noh1 1College of Pharmacy, Ajou University, Yeongtong-gu, Suwon, Republic of Korea; 2Research Institute of Pharmaceutical Science and Technology (RIPST), Ajou University, Yeongtong-gu, Suwon, Republic of Korea Background: Several clinical trials have shown an increased ris...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2018-05-01
|
| Series: | Therapeutics and Clinical Risk Management |
| Subjects: | |
| Online Access: | https://www.dovepress.com/increased-risk-of-adverse-drug-events-secondary-to-bevacizumab-treatme-peer-reviewed-article-TCRM |